WO2017168390A3 - Attenuation of neurodegeneration associated with parkinson's disease by inhibition of the dopamine d3 receptor in cd4+ t cells - Google Patents

Attenuation of neurodegeneration associated with parkinson's disease by inhibition of the dopamine d3 receptor in cd4+ t cells Download PDF

Info

Publication number
WO2017168390A3
WO2017168390A3 PCT/IB2017/051868 IB2017051868W WO2017168390A3 WO 2017168390 A3 WO2017168390 A3 WO 2017168390A3 IB 2017051868 W IB2017051868 W IB 2017051868W WO 2017168390 A3 WO2017168390 A3 WO 2017168390A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
dopamine
receptor
parkinson
attenuation
Prior art date
Application number
PCT/IB2017/051868
Other languages
French (fr)
Other versions
WO2017168390A2 (en
Inventor
Rodrigo PACHECO
Hugo GONZÁLEZ
Daniela ELGUETA
Francisco CONTRERAS
Valentina UGALDE
Original Assignee
Fundación Ciencia Para La Vida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundación Ciencia Para La Vida filed Critical Fundación Ciencia Para La Vida
Publication of WO2017168390A2 publication Critical patent/WO2017168390A2/en
Publication of WO2017168390A3 publication Critical patent/WO2017168390A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/80—Neurotransmitters; Neurohormones
    • C12N2501/815—Dopamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Method for preventing or treating neurodegenerative diseases, based in treating in vitro or ex vivo CD4+ T cells obtained from a subject, with a dopamine D3 (D3R) receptor inhibitor compound, and reincorporating the pre-treated CD4+ T cells to the subject, in an autologous transplant.
PCT/IB2017/051868 2016-03-31 2017-03-31 Attenuation of neurodegeneration associated with parkinson's disease by inhibition of the dopamine d3 receptor in cd4+ t cells WO2017168390A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL00753-2016 2016-03-31
CL2016000753A CL2016000753A1 (en) 2016-03-31 2016-03-31 Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells.

Publications (2)

Publication Number Publication Date
WO2017168390A2 WO2017168390A2 (en) 2017-10-05
WO2017168390A3 true WO2017168390A3 (en) 2017-11-16

Family

ID=59963679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/051868 WO2017168390A2 (en) 2016-03-31 2017-03-31 Attenuation of neurodegeneration associated with parkinson's disease by inhibition of the dopamine d3 receptor in cd4+ t cells

Country Status (2)

Country Link
CL (1) CL2016000753A1 (en)
WO (1) WO2017168390A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016474A1 (en) * 2019-07-23 2021-01-28 Fundación Ciencia Para La Vida (Fcv) Ibd therapy by inhibition of drd3 in regulatory t cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050163773A1 (en) * 2001-10-29 2005-07-28 Mia Levite Methods and pharmaceutical compositions for dopaminergic modulation of t-cell adhesion and activity
US20060246042A1 (en) * 1998-11-16 2006-11-02 Alison Davies Cells, culture methods, and their use in autologous transplantation therapy
US20100068138A1 (en) * 2002-09-14 2010-03-18 Amy Newman Structurally rigid dopamine d3 receptor selective ligands and process for making them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246042A1 (en) * 1998-11-16 2006-11-02 Alison Davies Cells, culture methods, and their use in autologous transplantation therapy
US20050163773A1 (en) * 2001-10-29 2005-07-28 Mia Levite Methods and pharmaceutical compositions for dopaminergic modulation of t-cell adhesion and activity
US20100068138A1 (en) * 2002-09-14 2010-03-18 Amy Newman Structurally rigid dopamine d3 receptor selective ligands and process for making them

Also Published As

Publication number Publication date
WO2017168390A2 (en) 2017-10-05
CL2016000753A1 (en) 2017-11-10

Similar Documents

Publication Publication Date Title
MX2020012797A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use.
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
WO2015183920A3 (en) Methods and systems for converting precursor cells into gastric tissues through directed differentiation
EP4292600A3 (en) Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
EP3600355A4 (en) Methods to protect transplanted tissue from rejection
MX2014012945A (en) Pyrazole aminopyrimidine derivatives as lrrk2 modulators.
MX2023004151A (en) Agricultural compositions for improved crop productivity and enhanced phenotypes.
MX2021007515A (en) Heterocyclyl pyridazine as fungicidal compounds.
WO2012149484A3 (en) Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate
WO2010037041A3 (en) Frizzled-binding agents and uses thereof
EP3890474A4 (en) Hemp plant named 'cw1as1'
MX2021000459A (en) Method for producing î³î´ t cells.
MX2023004969A (en) METHODS FOR TREATING AND PREVENTING<i> C. DIFFICILE </i>INFECTION.
WO2017214170A3 (en) Baff-r antibodies and uses thereof
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
WO2016176620A8 (en) Extracellular matrix compositions for the treatment of cancer or immunological diseases
EP3473642A3 (en) Compositions and methods of using islet neogenesis peptides and analogs thereof
MX2021000066A (en) Methods and compositions for preparing tagatose from fructose.
IL289094A (en) Tetrazines for high click release speed and yield
MX2020005640A (en) Humanized anti-liv1 antibodies for the treatment of breast cancer.
JOP20200295A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and there uses
EP3732286A4 (en) Generation of induced pluripotent cells by crispr activation
WO2017136731A8 (en) Rapaglutins, novel inhibitors of glut and use thereof
WO2017112422A8 (en) In situ treatment of seed in furrow
MX2020011986A (en) Compositions comprising glucose and hemicellulose and their use.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17773423

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17773423

Country of ref document: EP

Kind code of ref document: A2